Docstoc - Biomarkers in Alzheimers Disease_ 2011

Document Sample - Biomarkers in Alzheimers Disease_ 2011 Powered By Docstoc announces, a new market research report is available in its vast collection:

                    Biomarkers in Alzheimers Disease, 2011


This report provides an overview of biomarkers associated with Alzheimer’s disease (AD) that have
potential in differential diagnosis, in following treatment, in clinical trials and drug discovery. These
include molecules found in CSF and blood, genotypes, image-based parameters and others.

AD biomarkers offer utility in a number of ways: identification of groups at risk of developing AD;
early detection of AD; differentiation of different forms of neurodegenerative disease from AD, as well
as developmental stages (such as MCI), thought to progress to AD; supporting specific treatments or
pharmacological interventions; following the time-course progression of AD and response to therapy;
assessing patient prognosis; advancing understanding of the disease, including risk factors, and the
changes that precede its development; the identification of new drug targets and candidate molecules;
development of discovery assays for efficacy or toxicity markers; and supporting the recruitment of
subjects most likely to provide a meaningful analysis of treatment effects. These areas are, therefore,
considered and discussed in relation to the AD biomarkers presented in this report.

Of the biomarker areas being researched, the goal of developing methods for the early detection of
AD, including the prediction of risk in particular patient groups, is a key priority. It is believed that the
first symptoms of AD – generally diagnosed using cognitive, behavioural and functional assessments –
occur after significant neuronal loss has already occurred. Consequently, it is thought that patients
diagnosed at this stage will be less likely to gain benefits from treatment. This also hampers the
development of disease-altering therapies, because, without adequate comparators (e.g. showing
those who have the disease, or a particular developmental stage such as MCI, compared to healthy
controls), it is difficult or impossible to evaluate treatment effects. Therefore, in the preparation of this
report, emphasis was given to identifying biomarkers with potential in the early detection of the
disease, or alternatively, in differentiating different stages or types of neurodegenerative disease,
thought to be related to AD.

This Report

There are many AD biomarker studies; a report of this nature can provide only a general overview.
More than 750 studies have been reviewed in its preparation (up to January 2011), and the findings
from a short-list of approximately 150 studies are presented and discussed. The key goals of this
report are practical in nature – to identify biomarkers that show the greatest potential in advancing
research and development in the diagnosis and treatment of AD. The goals are as follows:
a) to review studies published over the last decade (up to Jan 2011) for short-listing;
b) to identify controlled clinical studies relating to AD and/or neurodegenerative conditions or stages
believed to precede AD (e.g. MCI), that included the study of biomarkers (blood, CSF, genetic, image-
based and others); and
c) to short-list opportunities to develop tests in the areas of utility indicated, with a particular
emphasis on the early detection of AD or following disease progression.

Significant advances in this field have occurred in recent years. While considerable effort has focused
on Abeta and tau related markers, a substantial number of other molecules and parameters have been
identified, that may offer opportunities. Increasingly, correlations are also being seen between
different types such as imaging and species found in CSF. This report identifies 99 candidate AD
biomarkers and their associated studies. These were identified in CSF (40) and blood (18), using
imaging (25) or genotypes (11), and others (5). Approximately 30 percent were linked with the early
detection of AD.

Table of Contents:

Chapter 1 Background p.25

1. Alzheimer’s Disease
1.1 Statistics and Costs
1.2 Histopathology
1.3 Amyloid Beta (Abeta)
1.4 Tau Proteins and Neurofibrillary Tangles
1.5 Cholinergic Hypothesis
1.6 Diagnosis
1.7 Cognitive Tests
1.8 Stages of Alzheimer’s Disease
1.9 Treatment of AD
1.10 Biomarkers
1.11 Genetics
1.12 Autoantibodies
1.13 Blood Brain Barrier
1.14 Pathogenesis of Alzheimer’s disease

References (Chapter 1)

Chapter 2 CSF Biomarkers and Diagnosis p.45

2.1 - 2.12
References (Chapter 2)

Chapter 3 Blood Biomarkers and Diagnosis p.62

3.0 - 3.12
References (Chapter 3)

Chapter 4 CSF Biomarkers and Early-Detection p.74

More Related Reports :

 VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011

 Biomarkers in Alzheimers Disease, 2011

 Alzheimers Disease: Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011

 Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

 Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

 Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011

 Image-Based Biomarkers in Alzheimers Disease, 2011
 Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical

 Lung Cancer Vaccines: Pipeline, Strategies and Clinical

 Lung Cancer Vaccines: Pipeline, Strategies and Clinical

 Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical

 Biomarkers in Parkinsons Disease, 2011

 Biomarkers in Breast Cancer, 2011

For More details about above & other Reports plz contact :


Contact: Marketing team





Shared By: